Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug
https://doi.org/10.14412/2074-2711-2020-2-125-130
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the main class of analgesics for the relief of acute nonspecific back pain (NSBP) and for the control of chronic one (CNSBP). The choice of a NSAID is determined by the efficacy, ease of use, and safety profile of a particular drug. Etoricoxib is one of the most successful representatives of NSAIDs, which is advisable to be used in CNSBP. Double-blind, controlled studies of patients with CNSBP have indicated that etoricoxib at a dose of 60 mg/day is significantly superior to placebo and that at a dose of 150 mg/day is not inferior to diclofenac. The important advantages of etoricoxib are its good tolerance and a relatively low risk of gastrointestinal complications. The frequency of cardiovascular and renal complications with etoricoxib is not higher than those with the most popular nonselective NSAIDs. In 2020, etoricoxib was included in the number of official indications approved by the Ministry of Health of Russia for the treatment of chronic lower back pain.
About the Author
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115552, Russia
Russian Federation
34A, Kashirskoe Shosse, Moscow 115552, Russia
References
1. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4–11. (In Russ.) doi: 10.14412/2074-2711-2018-2-4-11
2. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7): 514-530. doi: 10.7326/M16-2367. Epub 2017 Feb 14.
3. Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018 Nov; 27(11):2791-2803. doi: 10.1007/s00586-018-5673-2. Epub 2018 Jul 3.
4. Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ. 2017 Jan 6;356:i6748. doi: 10.1136/bmj.i6748.
5. Allegri M, Montella S, Salici F, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11];5. pii: F1000 Faculty Rev-1530. eCollection 2016.
6. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159): 1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.
7. Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11): 1688-1694. doi: 10.1002/acr.22890.
8. Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009 Jan-Feb;22(1): 62-8. doi: 10.3122/jabfm.2009.01.080102.
9. Langenmaier AM, Amelung VE, Karst M, et al. Subgroups in chronic low back pain patients – a step toward cluster-based, tailored treatment in inpatient standard care: On the need for precise targeting of treatment for chronic low back pain. Ger Med Sci. 2019 Sep 11;17:Doc09. doi: 10.3205/000275. eCollection 2019.
10. Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2):216-241.
11. Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain. 2016 Sep;17(9 Suppl):T50-69. doi: 10.1016/j.jpain.2016.03.001.
12. Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Apr 4;166(7):480-492. doi: 10.7326/M16-2458. Epub 2017 Feb 14.
13. Ramos-Remus CR, Hunsche E, Mavros P, et al. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin. 2004 May;20(5):691-8.
14. Sheldon EA, Bird SR, Smugar SS, Tershakovec AM. Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain. Spine (Phila Pa 1976). 2008 Mar 1;33(5):533-8. doi: 10.1097/BRS.0b013e3181657d24.
15. Peloso PM, Moore RA, Chen WJ, et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scand J Pain. 2016 Oct;13: 175-181. doi: 10.1016/j.sjpain.2016.07.002. Epub 2016 Aug 10.
16. Kuritzky L, Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi: 10.2147/JPR.S6775. Epub 2012 Nov 28.
17. O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009 Nov-Dec; 37(6):1789-802.
18. Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9): 872-882. doi: 10.1001/jama.2018.0899.
19. Ahmedani BK, Peterson EL, Wells KE, et al. Long-term Management of Low Back Pain with Opioids and Non-steroidal Anti-inflammatory Drugs in a Health System. Am J Prev Med. 2016 Jun;50(6):e191-e193. doi: 10.1016/j.amepre.2016.02.001. Epub 2016 Mar 9.
20. Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi: 10.1002/14651858
21. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1S):1-29. (In Russ.) doi: 10.14412/1995-4484-2018-1-29
22. Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12.
23. Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20.
24. Kwiatkowska B, Majdan M, MastalerzMigas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6):290-297. doi: 10.5114/reum.2017.72626. Epub 2017 Dec 30.
25. Davydov OS. The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase-2 inhibition in the prevention of pain syndrome chronization. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):10–6. (In Russ.) doi: 10.14412/2074-2711-2016-2-10-16
26. Piirainen A, Kokki M, Hautajä rvi H, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul; 36(7):545-55. doi: 10.1007/s40261-016-0400-4.
27. Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi: 10.1186/s12891-016-1170-0.
28. Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi: 10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.
29. Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov; 28(6):1021-1028. doi: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.
30. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.
31. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi: 10.1097/j.pain.0000000000000562.
32. Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Aug 2. pii: S1063-4584(17)31091-9.
33. Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003 Aug;4(6):307-15.
34. Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66.
35. Moore RA, Smugar SS, Wang H, et al. Numbers-needed-to-treat analyses – do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain. 2010 Dec;151(3): 592-7. doi: 10.1016/j.pain.2010.07.013.
36. Zerbini C, Ozturk ZE, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, doubleblind study. Curr Med Res Opin. 2005 Dec; 21(12):2037-49.
37. Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005 May;21(5):715-22.
38. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi: 10.1371/journal.pone.0190798. eCollection 2018.
39. Karateev AE, Pogozheva EYu, Filatova ES, Amirdzhanova VN. Endoscopic picture of the upper gastrointestinal tract against the background of taking various non-steroidal antiinflammatory drugs. Klinicheskaya farmakologiya i terapiya. 2018;27(4):40-5. (In Russ.)
40. Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006 Dec;22(12): 2365-74.
41. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81.
42. Karateev AE. Destabilized hypertension as a complication of therapy with nonsteroidal antiinflammatory drugs: the importance of the problem. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(2):64-72. (In Russ.). doi: 10.14412/1996-7012-2018-2-64-72
43. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79.
44. Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016 Sep 8:1-14.
45. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004 Jan;26(1):70-83.
Review
Supporting agencies: This article has been supported by MSD.
For citations:
Karateev A.E. Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):125-130. (In Russ.) https://doi.org/10.14412/2074-2711-2020-2-125-130
Views: 3277
Email this article 